Varengold Bank AG

  • WKN: 547930
  • ISIN: DE0005479307
  • Land: Germany

Nachricht vom 13.07.2021 | 14:00

Varengold Bank AG continues growth in the 1st half of 2021

DGAP-News: Varengold Bank AG / Key word(s): Half Year Results/Miscellaneous
13.07.2021 / 14:00
The issuer is solely responsible for the content of this announcement.

  • Net income almost doubled
  • EBT increased by 400%
  • Forecast EBT of EUR 16.4 million for 2021 confirmed

Hamburg, 13/07/2021 - Varengold Bank AG [ISIN: DE0005479307] continues to grow. In the first half of 2021, the Hamburg-based financial services provider almost doubled its net income to EUR 24.75 million (30 June 2020: EUR 12.97 million). Varengold Bank was able to increase its earnings before taxes (EBT) by 400% to EUR 8.12 million (30 June 2020: EUR 1.63 million). Once again, Transaction Banking proved to be a key growth driver. Within Marketplace Banking, the bank's second strategic growth market, there is further reason to be optimistic about the future: within the areas of "Lending" and "Fronting/Banking as a Service (BaaS)", additional customers have been acquired and the product range has been expanded.

To manage its growth, Varengold Bank is continuously working on refining its profile as an employer, in order to gain a competitive edge and attract the best professionals. This has proven to be successful. As of 30 June 2021, the Bank employed 102 highly qualified staff in Hamburg, Sofia and London. At the end of 2020, Varengold employed 91 staff at all three locations.

Varengold Bank continues to pursue a conservative risk policy and will continue to use part of its earnings to hedge risks in the first half of 2021. When considering its business development during the first half of 2021 as well as its well-filled transaction pipeline, the Bank continues to expect to achieve the forecasted EBT of EUR 16.4 million for 2021.

 

About Varengold Bank AG
Varengold Bank is a German financial institution founded in 1995 and granted a full banking licence in 2013. In addition to its head office in Hamburg, the bank has presences in London and Sofia. Core business areas are Marketplace Banking and Commercial Banking. Within Marketplace Banking, the focus is on the cooperation with European fintechs, especially lending platforms. Varengold Bank's service portfolio includes Funding, Debt and Equity Capital Markets products, Fronting Services for products subject to banking licence requirements and International Payment Services. Varengold Bank is registered with the Federal Financial Supervisory Authority (BaFin) under no. 109 520 and its shares (ISIN: DE0005479307) have been listed on the Open Market of the Frankfurt Stock Exchange since 2007. For more information, see www.varengold.de.

 

Disclaimer
This release contains forward-looking statements that involve certain risks and uncertainties. Future results may differ materially from those currently anticipated due to various risk factors and uncertainties, such as changes in business, economic and competitive conditions, currency exchange rate fluctuations, litigation uncertainties or investigations, and availability of financial resources. Varengold Bank AG assumes no responsibility for updating the forward-looking statements contained in this release.


Contact:
Ms. Sanja Schultz-Szabo (Head of Corporate Development)


13.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021